{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:46:15Z","timestamp":1760298375155,"version":"3.37.3"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1124\/dmd.111.038620","type":"journal-article","created":{"date-parts":[[2011,6,15]],"date-time":"2011-06-15T04:38:50Z","timestamp":1308112730000},"page":"1486-1494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Hepatic UDP-Glucuronosyltransferase Is Responsible for Eslicarbazepine Glucuronidation"],"prefix":"10.1016","volume":"39","author":[{"given":"Ana I.","family":"Loureiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Fernandes-Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J.","family":"Bonif\u00e1cio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyndon C.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricio","family":"Soares-da-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.111.038620_bib1","series-title":"The Treatment of Epilepsy","first-page":"485","article-title":"Eslicarbazepine acetate","author":"Almeida","year":"2009"},{"key":"10.1124\/dmd.111.038620_bib2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1600-0404.2009.01233.x","article-title":"Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects","volume":"121","author":"Almeida","year":"2010","journal-title":"Acta Neurol Scand"},{"key":"10.1124\/dmd.111.038620_bib3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00228-007-0414-1","article-title":"Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment","volume":"64","author":"Almeida","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.111.038620_bib4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.nurt.2006.10.005","article-title":"Eslicarbazepine acetate (BIA 2\u2013093)","volume":"4","author":"Almeida","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1124\/dmd.111.038620_bib5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","article-title":"Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy","volume":"89","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Research"},{"key":"10.1124\/dmd.111.038620_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2125.1997.00607.x","article-title":"The mechanism of the carbamazepine-valproate interaction in humans","volume":"44","author":"Bernus","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.111.038620_bib7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.metabol.2006.01.006","article-title":"N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II","volume":"55","author":"Borlak","year":"2006","journal-title":"Metabolism"},{"key":"10.1124\/dmd.111.038620_bib8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1124\/dmd.106.013052","article-title":"The glucuronidation of Delta4-3-Keto C19- and C21-hydroxysteroids by human liver microsomal and recombinant UDP-glucuronosyltransferases (UGTs): 6alpha- and 21-hydroxyprogesterone are selective substrates for UGT2B7","volume":"35","author":"Bowalgaha","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038620_bib9","first-page":"103","article-title":"Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures","volume":"6","author":"Brown","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"10.1124\/dmd.111.038620_bib10","series-title":"Procedure No. EMEA\/H\/C\/000988 (EMEA\/304525\/2009 DR ed","first-page":"80","article-title":"CHMP assessment report for Zebinix (eslicarbazepine acetate)","year":"2009"},{"key":"10.1124\/dmd.111.038620_bib11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0090-9556(25)07335-0","article-title":"Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family","volume":"21","author":"Ebner","year":"1993","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038620_bib12","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"key":"10.1124\/dmd.111.038620_bib13","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0006-2952(03)00076-5","article-title":"The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases","volume":"65","author":"Ethell","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.111.038620_bib14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00044011-200424040-00001","article-title":"Overview of the clinical pharmacokinetics of oxcarbazepine","volume":"24","author":"Flesch","year":"2004","journal-title":"Clin Drug Investig"},{"key":"10.1124\/dmd.111.038620_bib15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0404.2009.01218.x","article-title":"Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures","volume":"120","author":"Gil-Nagel","year":"2009","journal-title":"Acta Neurol Scand"},{"key":"10.1124\/dmd.111.038620_bib16","first-page":"507","article-title":"Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3","volume":"26","author":"Green","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038620_bib17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0920-1211(01)00231-5","article-title":"Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(\u2212)-10,11-dihydro-10-hydroxy carbamazepine","volume":"44","author":"Hainzl","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1124\/dmd.111.038620_bib18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/00498250110057341","article-title":"Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin","volume":"31","author":"Hanioka","year":"2001","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.111.038620_bib19","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00228-003-0558-6","article-title":"Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects","volume":"58","author":"Hermann","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.111.038620_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/toxsci\/61.1.49","article-title":"Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac","volume":"61","author":"King","year":"2001","journal-title":"Toxicol Sci"},{"key":"10.1124\/dmd.111.038620_bib21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/toxsci\/kfi211","article-title":"Phenobarbital and phenytoin increased acetaminophen hepatotoxicity due to inhibition of UDP-glucuronosyltransferases in cultured human hepatocytes","volume":"87","author":"Kostrubsky","year":"2005","journal-title":"Toxicol Sci"},{"key":"10.1124\/dmd.111.038620_bib22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.fpc.0000173483.13689.56","article-title":"Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily","volume":"15","author":"Mackenzie","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.111.038620_bib23","first-page":"275","article-title":"Characterization of the metabolites of carbamazepine in patient urine by liquid chromatography\/mass spectrometry","volume":"25","author":"Maggs","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038620_bib24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5414\/CPP46119","article-title":"Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate","volume":"46","author":"Maia","year":"2008","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.038620_bib25","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1124\/dmd.30.6.636","article-title":"Imipramine N-glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDP-glucuronosyltransferase isoforms","volume":"30","author":"Nakajima","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038620_bib26","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1124\/dmd.107.015909","article-title":"Stereoselective glucuronidation of 5-(4\u2032-hydroxyphenyl)-5-phenylhydantoin by human UDP-glucuronosyltransferase (UGT) 1A1, UGT1A9, and UGT2B15: effects of UGT-UGT interactions","volume":"35","author":"Nakajima","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038620_bib27","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1185\/03007991003740861","article-title":"Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects","volume":"26","author":"Nunes","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1124\/dmd.111.038620_bib28","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2165\/00003088-199631060-00005","article-title":"Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations","volume":"31","author":"Riva","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.111.038620_bib29","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","article-title":"In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction","volume":"34","author":"Rowland","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038620_bib30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1124\/jpet.106.118216","article-title":"Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation","volume":"321","author":"Rowland","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.038620_bib31","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1124\/jpet.104.073114","article-title":"N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7","volume":"311","author":"Staines","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.038620_bib32","doi-asserted-by":"crossref","first-page":"36164","DOI":"10.1074\/jbc.M002180200","article-title":"Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine","volume":"275","author":"Strassburg","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.111.038620_bib33","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1124\/dmd.31.5.670","article-title":"Glucuronidation activity of the UGT2B17 enzyme toward xenobiotics","volume":"31","author":"Turgeon","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038620_bib34","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1124\/dmd.105.007369","article-title":"Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) \u201cprobes\u201d for human UDP-glucuronosyltransferases","volume":"34","author":"Uchaipichat","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038620_bib35","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2125.2006.02588.x","article-title":"Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation","volume":"61","author":"Uchaipichat","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.111.038620_bib36","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1124\/dmd.106.012815","article-title":"Glucuronidation of anti-HIV drug candidate bevirimat: identification of human UDP-glucuronosyltransferases and species differences","volume":"35","author":"Wen","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038620_bib37","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1124\/dmd.106.009399","article-title":"N-glucuronidation of perfluorooctanesulfonamide by human, rat, dog, and monkey liver microsomes and by expressed rat and human UDP-glucuronosyltransferases","volume":"34","author":"Xu","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038620_bib38","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S0090-9556(24)15026-X","article-title":"Human and Escherichia coli beta-glucuronidase hydrolysis of glucuronide conjugates of benzidine and 4-aminobiphenyl, and their hydroxy metabolites","volume":"27","author":"Zenser","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.038620_bib39","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1124\/dmd.107.017962","article-title":"Characterization of 1\u2032-hydroxymidazolam glucuronidation in human liver microsomes","volume":"36","author":"Zhu","year":"2008","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624224442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624224442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.111.038620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T20:00:03Z","timestamp":1739908803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624224442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0090955624224442"],"URL":"https:\/\/doi.org\/10.1124\/dmd.111.038620","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic UDP-Glucuronosyltransferase Is Responsible for Eslicarbazepine Glucuronidation","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.111.038620","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}